Yiwei Chu
Impact in
- Immunology top 0.5%
- T-cell and B-cell Immunology
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
- Immunology 90
- T-cell and B-cell Immunology 43
- Immunotherapy and Immune Responses 31
- Immune Response and Inflammation 10
- Immune cells in cancer 10
- Oncology 41
- Cancer Immunotherapy and Biomarkers 20
- CAR-T cell therapy research 8
- Co-authors
- Feifei Luo (24 shared papers)Sidong Xiong (29 shared papers)Luman Wang (29 shared papers)Ronghua Liu (17 shared papers)熊术道 (10 shared papers)Xue Yang (5 shared papers)Yijie Zheng (9 shared papers)Ronghua Liu (15 shared papers)
- Journals
- Frontiers in Immunology (7 papers)Oncotarget (6 papers)DNA and Cell Biology (5 papers)PLoS ONE (5 papers)Cancer Immunology Immunotherapy (5 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Yiwei Chu
185 papers receiving 8.7k citations
Yiwei Chu's Hit Papers
Peers
Comparison fields: 5 of 115
- Immunology 2.2k
- Oncology 2k
- Cancer Research 897
- Geriatrics and Gerontology 209
- Genetics 374
Countries citing papers authored by Yiwei Chu
This map shows the geographic impact of Yiwei Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yiwei Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yiwei Chu more than expected).
Fields of papers citing papers by Yiwei Chu
This network shows the impact of papers produced by Yiwei Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yiwei Chu. The network helps show where Yiwei Chu may publish in the future.
Co-authors
The 25 scholars most cited alongside Yiwei Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 189 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3–CCL2 Signaling Hit paper breakdown → | 2016 | 631 |
| 2 | Th17 and natural Treg cell population dynamics in systemic lupus erythematosus Hit paper breakdown → | 2009 | 403 |
| 3 | 2017 | 291 | |
| 4 | 2018 | 221 | |
| 5 | 2012 | 220 | |
| 6 | 2008 | 186 | |
| 7 | 2013 | 186 | |
| 8 | 2011 | 171 | |
| 9 | 2014 | 164 | |
| 10 | 2018 | 150 | |
| 11 | 2020 | 148 | |
| 12 | 2005 | 144 | |
| 13 | 2007 | 120 | |
| 14 | 2011 | 107 | |
| 15 | 2014 | 102 | |
| 16 | 2012 | 100 | |
| 17 | 2015 | 100 | |
| 18 | 2014 | 99 | |
| 19 | 2012 | 96 | |
| 20 | 2014 | 96 |
About Yiwei Chu
Yiwei Chu is a scholar working on Immunology, Oncology, Cancer Research, Rheumatology and Molecular Biology, having authored 189 papers that have together received 8.9k indexed citations. Recurring topics across this work include T-cell and B-cell Immunology (43 papers), Immunotherapy and Immune Responses (31 papers), Cancer Immunotherapy and Biomarkers (20 papers), Immune Response and Inflammation (10 papers), Immune cells in cancer (10 papers), MicroRNA in disease regulation (10 papers), Inflammatory Bowel Disease (9 papers) and CAR-T cell therapy research (8 papers). The work is most often cited by research in Immunology (2.2k citations), Oncology (2k citations), Cancer Research (897 citations), Geriatrics and Gerontology (209 citations) and Genetics (374 citations). Yiwei Chu has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Feifei Luo, Sidong Xiong, Luman Wang, Ronghua Liu, 熊术道, Xue Yang, Yijie Zheng, Ronghua Liu, Rui He and Ji Young Yang. Their work appears in journals such as Frontiers in Immunology, Oncotarget, DNA and Cell Biology, PLoS ONE and Cancer Immunology Immunotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.